防风通圣散对乙型肝炎慢加急性(亚急性)肝衰竭早期的临床干预研究

Study of clinical intervention on early stage of HBV related acute-on-chronic liver failur with fangfengtongsheng powder

目的:研究防风通圣散对乙型肝炎慢加急性(亚急性)肝衰竭患者早期(两周)的治疗作用。方法:回顾性分析该类患者53例,其中对照组19例,观察组34例。对照组患者采用基础治疗加抗病毒治疗;观察组患者在对照组基础上加服防风通圣散中药汤剂,观察时间为两周。观察两组患者治疗前后肝功能和凝血功能变化及治疗效果。结果:两组患者肝功能及凝血功能较治疗前均有显著改善(P<0.01);在治疗两周时观察组患者在转氨酶、胆红素、PT降低及PTA升高方面与对照组比较,差异有显著性意义(P<0.01);治疗第1周时(73.52%vs 42.11%)及第2周时(94.11%vs 68.42%)的好转率,观察组均优于对照组(P<0.05)。3个月后随访期结果显示观察组患者获得更高治愈的可能。结论:乙型肝炎慢加急性(亚急性)肝衰竭早期(两周内)在综合治疗基础上,使用防风通圣散可有效阻止病情进展,提高临床疗效。

objective：To understand the clinical intervention on early stage of HBV related acute-on-chronic liver failur with fangfengtong- sheng powder. Methods：A retrospective analysis of 53 cases of early stage of HBV related ACLF, including 19 cases in the control group, and 34 cases in the observation group of Fangfengtongsheng Powder. To compare the the liver function and coagulation function before and af- ter treatment in patients between the two groups. The effective rates of the two groups were also compared. Results ：Two groups of liver func- tion and coagulation function were significantly improved than before treatment （ P 〈 0. O1 ）. In the second week of the observation group in the reduction of serum aminotransferase and bilirubin, PT decreased, PTA increased compared with the control group, there were significant differences （P 〈0.01 ）. The improvement rate of first week （73.52% vs 42.11% ） and second week （94.11% vs 68.42% ） in the observa- tion group were better than those in the control group （ P 〈 0.05 ）. Results for 3 months follow-up showed that the observation group had a higher chance of healing than the control group. Conclusion： Based on the comprehensive treatment of early stage of HBV related ACLF, u- sing Fangfeng Tongsheng Powder could effectively prevent disease progression.